Search
Vortioxetine
go.drugbank.com/drugs/DB09068ApprovedInvestigationalMore specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B … receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular...
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalMirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condit...
Synonyms: PD 0325901, PD-0325901Categories: P-glycoprotein substratesLevonorgestrel
go.drugbank.com/drugs/DB00367ApprovedInvestigationalLevonorgestrel (LNG) is a synthetic progestogen similar to Progesterone used in contraception and hormone therapy. Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released fr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAluminum chlorohydrex propylene glycol
go.drugbank.com/drugs/DB11208ApprovedAluminum chlorohydrex propylene glycol is a complex consisting of Aluminum Chorohydrate and propylene glycol (PG).
Vamotinib
go.drugbank.com/drugs/DB15396InvestigationalVamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With … Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Categories: Calcitonin Gene-Related Peptide Receptor Antagonists, P-glycoprotein substratesMolibresib
go.drugbank.com/drugs/DB16239InvestigationalMolibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigationalAnthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived f...
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "co...
Synonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidideCategories: P-glycoprotein inhibitors, P-glycoprotein substrates